A TRPM4 Inhibitor 9-Phenanthrol Inhibits Glucose- and Glucagon-Like Peptide 1-Induced Insulin Secretion from Rat Islets of Langerhans

Zuheng Ma, Anneli Björklund, and Md. Shahidul Islam

1Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden
2Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Research Center, 3rd Floor, 118 83 Stockholm, Sweden
3Department of Emergency Care and Internal Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden

Correspondence should be addressed to Md. Shahidul Islam; shahidul.islam@ki.se

Received 26 May 2017; Revised 18 August 2017; Accepted 10 September 2017; Published 2 October 2017

Pancreatic β-cells express several ion channels of the transient receptor potential family, which play important roles in mediating the stimulus-secretion coupling. One of these channels, the TRPM4 is a Ca2+-activated monovalent cation channel. This channel is inhibited by 9-phenanthrol, which also inhibits the TMEM16a Cl− channel, and activates the Ca2+-activated K+ channel, Kca3.1. The net effects of ion-channel modulation by 9-phenantherol on the insulin secretion remain unclear. We tested the effects of 9-phenanthrol on glucose- and GLP-1-induced insulin secretion from isolated rat islets in static incubations. When applied to the islets in the presence of 3.3 mM glucose, 9-phenanthrol caused a small increase in insulin secretion (~7% of the insulin secretion stimulated by 10 mM glucose). 10 μM 9-phenanthrol did not inhibit glucose- or GLP-1-induced insulin secretion. 20 μM and 30 μM 9-phenanthrol inhibited glucose-induced insulin secretion by ~80% and ~85%, respectively. Inhibition of the GLP-1-induced insulin secretion by 20 μM and 30 μM 9-phenanthrol was 65% and 94%, respectively. Our study shows that the major effect of 9-phenanthrol on the islets is a strong inhibition of insulin secretion, and we speculate that compounds related to 9-phenanthrol may be potentially useful in treating the pancreatogenous hyperinsulinemic hypoglycemia syndromes.

1. Introduction

Impairment of insulin secretion from the islets of Langerhans is one component of the mechanisms that underlie the pathogenesis of type 2 diabetes. The molecular mechanisms that lead to such impairments are not fully clear. Glucose, glucagon-like peptide-1 (GLP-1), and other insulin secretagogues stimulate secretion from the β-cells by involving a cascade of signaling events that are not fully understood. In this respect, depolarization of the plasma membrane potential, electrical activity, and Ca2+ signaling play pivotal roles in mediating the stimulus-secretion coupling in the β-cells.

Many ion channels, including the ATP-sensitive potassium (KATP) channels, and the voltage-gated Ca2+ channels participate in mediating the periodic electrical activity and Ca2+ signaling in the β-cell [1]. There is evidence suggesting that some channels of the transient receptor potential (TRP) family mediate inward cationic currents for depolarizing the plasma membrane potential of the β-cells [2]. Marabita and Islam demonstrated that human β-cells express at least eight TRP channels, for example, TRPC1, TRPM4, TRPM7, TRPM2, TRPM3, TRPP2, TRPML1, and TRPML3 [3]. TRPM4 and TRPM5 are two closely related nonselective cation channels permeable to the monovalent cations, but almost impermeable to the divalent ones. These channels are activated by the intracellular free Ca2+ ion concentration ([Ca2+]). Rat islets express both the TRPM4 and the TRPM5 channels. Krishnan et al. have shown that triphenylphosphine oxide, an inhibitor of the TRPM5 channel, inhibits insulin secretion from the rat islets [4]. Investigators have used 9-phenanthrol, a cell permeable hydroxytricyclic derivative, to test the effect of the inhibition of the TRPM4 channel...
on different physiological processes in many cells and tissues [5]. In contrast to the other inhibitors of TRPM4 channels, for example, glibenclamide and flufenamic acid, 9-phenanthrol is more selective for the TRPM4 channels. It inhibits the TRPM4 channels without inhibiting its closest relative, the TRPM5 channel, which is coexpressed with the TRPM4 channel in many cells [6].

Although 9-phenanthrol was initially discovered as an inhibitor of the TRPM4 channels, later studies showed that it also inhibits the transmembrane protein 16A (TMEM16A), a Ca2+-activated Cl− channel [7]. In addition, it activates the Ca2+-activated K+ channel (Kca3.1) [8]. All these actions of 9-phenanthrol on these three ion channels of the β-cells are expected to inhibit insulin secretion.

The effects of 9-phenanthrol on the insulin secretion from the rat islets have not been carefully studied. In this study, we demonstrate that 9-phenanthrol inhibits glucose- and GLP-1-induced insulin secretion from the isolated rat islets.

2. Materials and Methods

2.1. Chemicals. RPMI-1640 medium and other cell culture materials were purchased from Life Technologies, Stockholm, Sweden. Collagenase, 9-phenanthrol, and fetal bovine serum (FBS) were from Sigma-Aldrich, Stockholm, Sweden. Glucagon-like peptide 1 (7–37) was from Bachem, Switzerland.

2.2. Preparation of Islets from Rats. Ethical approval for the study was obtained from the Northern Stockholm ethical committee on experimental animal care. All the experiments were done following the guidelines of the Swedish National Board for Laboratory Animals. Male Sprague-Dawley rats were from Scanbur AB (Sollentuna, Sweden). We followed the ethical guidelines of the Karolinska Institute for the care and use of laboratory animals. The rats were kept in a 12-hour (6 a.m. to 6 p.m.) light/dark cycle with free access to standard diet and water. At the time of the experiments, the rats weighed 250 to 350 g.

The animals were humanely killed by inhalation of CO2. Collagenase (0.1% wt/vol) was injected into the pancreatic duct. The pancreas was digested by collagenase in Hank’s balanced salt solution. Islets were separated by centrifugation and density gradient separation with Histopaque 1077 and Histopaque 1119. The islets were handpicked by observing them under a stereomicroscope and kept in petri dishes containing RPMI-1640 medium, glucose (11 mM), glutamine (2 mM), FBS (10% vol/vol), benzylpenicillin (100 U/mL), and streptomycin (100 μg/mL) [4]. The islets were then cultured for 24 hours in an incubator at 37°C in 5% CO2. Later on, the islets were transferred to petri dishes containing 5 mL of Krebs-Ringer bicarbonate buffer, HEPES (10 mM), BSA (0.2%), and glucose (3.3 mM). On the day of the experiments, the islets were preincubated in this solution for 30 minutes at 37°C in 5% CO2.

2.3. Measurement of Insulin Secretion from the Islets. We chose islets that were of similar sizes on visual inspection, for all the experiments. The islets were incubated in groups of 3 in 300 μL of Krebs-Ringer bicarbonate buffer containing glucose (3.3, 10, or 16.7 mM), with or without other pharmacological agents, for 1 hour at 37°C in a water bath under continuous shaking. After 1 hour, the supernatant was carefully removed and stored at −20°C [4].

In separate experiments, we also measured the insulin contents of the islets and expressed the released insulin as percentage of the insulin content. The insulin content was measured after sonication of the islets for 10 to 15 seconds, followed by extraction of insulin overnight at 4°C in 200 μL of acid-ethanol (70% vol/vol).

Immunoreactive insulin was measured by radioimmunoassay using rat insulin as standard and insulin antibodies (Fitzgerald, United States).

2.4. Statistical Analysis. The results were expressed as mean, standard deviation (SD), and the 95% confidence interval (CI). One-way analysis of variance (ANOVA) with Sidak-Holm post hoc test was used for testing the statistical significance. Data were analyzed by means of the SigmaPlot package (Systat Software Inc., San Jose, CA, USA).

3. Results

Insulin secretion by 3.3 mM glucose was increased by 10 μM 9-phenanthrol (Figure 1(a)); mean insulin secretion (μU/islet/hour) by 3.3 mM glucose was 1.78 (SD 0.75, 95% CI 1.15–2.41, n = 8), and that in the presence of 10 μM 9-phenanthrol was 9.42 (SD 5.88, 95% CI 0.05–18.79, n = 4, P < 0.05). Thirty micromolar 9-phenanthrol also induced similar increase of basal insulin secretion (mean 6.75, SD 3.5, 95% CI 3.23–10.27, n = 4, P ≤ 0.05). However, the magnitude of the increased insulin secretion by 9-phenanthrol was small (only ~7% of the insulin secretion stimulated by 10 mM glucose).

To test whether the stimulatory effect of 9-phenanthrol on insulin secretion at low glucose was due to depolarization of the β-cells, we used diazoxide, which hyperpolarizes β-cells by activating the KATP channel, and found that diazoxide did not inhibit this effect of 9-phenanthrol. Mean insulin secretion (μU/islet/hour) in the presence of 3.3 mM glucose was 0.72 (SD 0.20, 95% CI 0.42–1.04, n = 4). Mean insulin secretion in the presence of 3.3 mM glucose plus 30 μM 9-phenanthrol was 1.95 (SD 0.79, 95% CI 0.69–3.21, n = 4), and that in the presence of 3.3 mM glucose, 30 μM 9-phenanthrol, and 100 μM diazoxide was 1.82 (SD 0.93, 95% CI 0.34–3.30, n = 4, P NS).

Stimulation of the islets with 10 mM glucose caused a 55-fold increase in insulin secretion compared to the secretion by 3.3 mM glucose (P ≤ 0.001) (Figure 1(a)) indicating that the islets were functionally intact. Insulin secretion stimulated by 10 mM glucose was not significantly inhibited by 10 μM 9-phenanthrol but was significantly inhibited by 20 μM and 30 μM 9-phenanthrol. Mean insulin secretion (μU/islet/hour) by 10 mM glucose was 98.75 (SD 27.69, 95% CI 75.60–121.90, n = 8), and that in the presence of 10 μM 9-phenanthrol was 76.50 (SD 14.47, 95% CI 53.47–99.53, n = 4, P NS). Mean insulin secretion by 10 mM glucose
in the presence of 20 μM 9-phenanthrol was 18.25 (SD 7.63, 95% CI 6.11–30.39, n = 4, P ≤ 0.001), and that in the presence of 30 μM 9-phenanthrol was 13.25 (SD 6.89, 95% CI 2.28–24.22, n = 4, P ≤ 0.001). Inhibition of insulin secretion by 20 μM 9-phenanthrol was not significantly different from that by 30 μM 9-phenanthrol.

We also tested the effect of 9-phenanthrol on insulin secretion stimulated by 16.7 mM glucose. Consistent with the results described above, 10 μM 9-phenanthrol did not, whereas 30 μM 9-phenanthrol did inhibit insulin secretion by 16.7 mM glucose (61% inhibition, P ≤ 0.001). Mean insulin secretion (μU/islet/hour) by 16.7 mM glucose was 71.33 (SD 12.85, 95% CI 39.46–103.2, n = 4); that in the presence of 10 μM 9-phenanthrol was 50.66 (SD 9.07, 95% CI 28.17–73.15, n = 4); and that in the presence of 30 μM 9-phenanthrol was 27.33 (SD 13.05, 95% CI –5.02–59.68, n = 4). Inhibition of secretion by higher concentrations of 9-phenanthrol, namely, 60 μM and 100 μM, was not significantly different from that by 30 μM 9-phenanthrol.

To control for the variability of the size and the insulin content of the islets, we calculated insulin secretion as percentage of the total insulin content of the islets (Figure 1(b)). Consistent with the results presented above, insulin secretion by 10 mM glucose was not significantly inhibited by 10 μM 9-phenanthrol but was significantly inhibited by 20 μM 9-phenanthrol (P ≤ 0.01) and 30 μM 9-phenanthrol (P ≤ 0.01). In the presence of 3.3 mM glucose, 10 μM and 30 μM 9-phenanthrol increased insulin secretion (P ≤ 0.05).

Figure 2 shows the effect of 9-phenanthrol on insulin secretion stimulated by 10 mM glucose plus 50 nM glucagon-like peptide 1 (GLP-1). GLP-1 increased glucose-induced insulin secretion by 110%. Mean insulin secretion (μU/islet/hour) by 10 mM glucose plus 50 nM GLP-1 was 208.12 (SD 47.40, 95% CI 168.49–247.65, n = 8), and that in the presence of 10 μM 9-phenanthrol was 190.00 (SD 23.33, 95% CI 152.85–227.12, n = 4, P NS). Mean insulin secretion (μU/islet/hour) by glucose plus GLP-1 in the presence of 20 μM 9-phenanthrol was 71.75 (SD 20.67, 95% CI 38.86–104.64, n = 4, P ≤ 0.001), and that in the presence of 30 μM of the inhibitor was 13.25 (SD 6.89, 95% CI 2.28–24.22, n = 4, P ≤ 0.001). Inhibition of GLP-1-induced insulin secretion by 20 μM 9-phenanthrol was 65% whereas that by 30 μM 9-phenanthrol was 94% (P ≤ 0.001). In another set of experiments, we tested the effect of 9-phenanthrol on insulin secretion when β-cells were maximally stimulated by 16.7 mM glucose plus 50 nM GLP-1 and found that 9-phenanthrol (30 μM) inhibited maximal insulin secretion by 88%. Insulin secretion (μU/islet/hour) in the presence of 16.7 mM glucose plus 50 nM GLP-1 was 325 (SD 73, 95% CI 209–441), and that in the presence of 16.7 mM glucose, 50 nM GLP-1 plus 30 μM 9-phenanthrol was 36.75 (SD 15.92, 95% CI 11.42–62.08, n = 4, P ≤ 0.001).
To test if the difference in insulin secretion could be due to the variability of the size or the insulin content of the islets, we measured insulin content of the islets and expressed insulin secretion as percentage of the insulin content (Figure 2(b)). When expressed this way, we found that 10 μM 9-phenanthrol did not significantly inhibit insulin secretion, whereas 20 μM and 30 μM 9-phenanthrol inhibited insulin secretion significantly (P ≤ 0.001).

To test the effect of the longer term exposure of the islets to 9-phenanthrol, we cultured the islets in the presence of 10 μM 9-phenanthrol for 24 hours. This treatment did not significantly alter the insulin secretion in response to 16.7 mM glucose or the insulin content of the islets compared to the control islets that were cultured without 9-phenanthrol. Mean insulin secretion (μU/islet/hour) in response to 16.7 mM glucose in the control islets was 1180.75 (SD 167.00, 95% CI 1076.32–1206.68, n = 4, P NS). However, when we cultured the islets in 30 μM 9-phenanthrol, for 24 hours, the islets appeared disintegrated on inspection under the microscope.

4. Discussion

The main finding of this study was that 9-phenanthrol inhibited glucose- and GLP-1-induced insulin secretion from the isolated rat islets in static incubations. When used at a concentration of 10 μM, 9-phenanthrol did not inhibit glucose- or GLP-1-induced insulin secretion significantly, but 20 μM and 30 μM 9-phenanthrol inhibited glucose-induced insulin secretion by ~80% and ~85%, respectively. Inhibition of the GLP-1-induced insulin secretion by 20 μM and 30 μM 9-phenanthrol was 65% and 94%, respectively. While the glucose-induced insulin secretion was maximally inhibited by 20 μM 9-phenanthrol, a higher concentration, that is, 30 μM was needed for maximal inhibition of the GLP-1-induced insulin secretion. The fact that 20–30 μM 9-phenanthrol inhibited insulin secretion is consistent with the fact that the inhibition of insulin secretion was due to the inhibition of the TRPM4 channels because the IC50 of 9-phenanthrol for the transfected or the endogenous TRPM4 channels has been shown to be 20–30 μM in many cells [5, 6]. The degree of inhibition of insulin secretion by 20–30 μM 9-phenanthrol is also consistent with the degree of inhibition of the activity of the TRPM4 channels by the similar concentrations of the substance reported in many cell types [5]. Glucose stimulation depolarizes the plasma membrane potential and increases the \([Ca^{2+}]_i\) in the β-cells; both of these events increase the activity of the TRPM4 channels. The inhibition of insulin secretion from rat islets by 9-phenanthrol is consistent with the roles of the TRPM4 channel in mediating electrical activity and insulin secretion that has been demonstrated in several rodent insulinoma cell lines [9]. More recently, Shigeto et al., by using a variety of methods including the use of 9-phenanthrol, have demonstrated that TRPM4 is involved in the GLP-1-induced insulin secretion from mouse islets [10].

Cruzen et al. have recently demonstrated that chloride efflux through a \(Ca^{2+}\)-activated \(Cl^-\) channel, anoctamin 1 (Ano1), also called “transmembrane member 16A” (TMEM16A), is involved in mediating the glucose-
stimulated insulin secretion [11]. As mentioned earlier, this channel is also inhibited by 9-phenanthrol at similar concentrations that inhibit the TRPM4 channel [7]. Activation of the Ca2+-activated K+ channel (Kca3.1) of the β-cells causes hyperpolarization of the plasma membrane potential and inhibits insulin secretion [12]. This channel is activated by 9-phenanthrol in the similar concentrations that inhibit the TRPM4 channel [8]. It is thus likely that the strong inhibition of insulin secretion by 9-phenanthrol in our study is the net result of the inhibition of the TRPM4 and the TMEM16A channels and the activation of the Kca3.1 channel.

We found that the effect of 9-phenanthrol on insulin secretion was glucose dependent. While it inhibited insulin secretion triggered by 10 or 16.7 mM glucose with or without GLP-1, it actually stimulated insulin secretion when applied to the islets in the presence of 3.3 mM glucose. The magnitude of this stimulation was however only 7% of the insulin secretion stimulated by 10 mM glucose. The mechanism of the stimulation of insulin secretion by 9-phenanthrol at low glucose is unclear. Our experiments with diazoxide suggest that this was not due to depolarization of the β-cells. It is also unlikely to be due to nonspecific toxic effect of the substance on the β-cells. In general, the substance shows low cellular toxicity [6]. It has been shown that the effect of 9-phenanthrol on the electrical activity of the cardiac muscle cells is reversible, further suggesting lack of any major toxic effects of the substance when used for experiments over short time [13]. We speculate that the stimulation of insulin secretion at 3.3 mM glucose could be due to the effect of 9-phenanthrol on the exocytotic machinery of the β-cell.

5. Conclusions

We have demonstrated that 9-phenanthrol, an inhibitor of the TRPM4 and the TMEM16A channels and an activator of the Kca3.1 channel, strongly inhibits both the glucose- and the GLP-1-induced insulin secretion. We speculate that compounds related to 9-phenanthrol could potentially be useful, for instance, in the development of drugs for the treatment of patients with pancreatogenous hyperinsulinemic hypoglycemia syndromes [14].

Conflicts of Interest

The authors declare that they have no conflicts of interest concerning the publication of this paper.

Authors’ Contributions

All the authors have been intellectually involved in generating the ideas, designing the experiments, analyzing the data, and writing the manuscript. Zuheng Ma has performed the experiments. All the authors have accepted responsibility for the entire content of the submitted manuscript and have approved submission.

Acknowledgments

Financial support was obtained from the Karolinska Institute, Stockholm, Sweden, and the Uppsala County Council, Uppsala University Hospital, Department of Emergency Care and Internal Medicine, Uppsala University, Sweden.

References

[1] M. S. Islam, "Calcium signaling in the islets," in Islets of Langerhans, M. S. Islam, Ed., pp. 605–632, Springer, Dordrecht, Heidelberg, New York, London, 2014.
[2] M. S. Islam, "TRP channels of islets," Advances in Experimental Medical Biology, vol. 704, pp. 811–830, 2011.
[3] F. Marabita and M. S. Islam, "Expression of transient receptor potential channels in the purified human pancreatic β-cells," Pancreas, vol. 46, no. 1, pp. 97–101, 2017.
[4] K. Krishnan, Z. Ma, A. Bjorklund, and M. S. Islam, "Role of transient receptor potential melastatin-like subtype 5 channel in insulin secretion from rat β-cells," Pancreas, vol. 43, no. 4, pp. 597–604, 2014.
[5] R. Guimard, T. Hof, and C. A. Del Negro, "The TRPM4 channel inhibitor 9-phenanthrol," British Journal of Pharmacology, vol. 171, no. 7, pp. 1600–1613, 2014.
[6] T. Grand, M. Demion, C. Norez et al., "9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels," British Journal of Pharmacology, vol. 153, no. 8, pp. 1697–1705, 2008.
[7] S. K. Burris, Q. Wang, S. Bulley, Z. P. Neeb, and J. H. Jaggar, "9-Phenanthrol inhibits recombinant and arterial myocyte TMEM16A channels," British Journal of Pharmacology, vol. 172, no. 10, pp. 2459–2468, 2015.
[8] C. J. Garland, S. V. Smirnov, P. Bagher et al., "TRPM4 inhibitor 9-phenanthrol activates endothelial cell intermediate conductance calcium-activated potassium channels in rat isolated mesenteric artery," British Journal of Pharmacology, vol. 172, no. 4, pp. 1114–1123, 2015.
[9] H. Cheng, A. Beck, P. Launay et al., "TRPM4 controls insulin secretion in pancreatic β-cells," Cell Calcium, vol. 41, no. 1, pp. 51–61, 2007.
[10] M. Shigeto, R. Ramracheya, A. I. Tarasov et al., "GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation," Journal of Clinical Investigation, vol. 125, no. 12, pp. 4714–4728, 2015.
[11] R. Crutzen, M. Virreira, N. Markadieu et al., "Anoctamin 1 (Ano1) is required for glucose-induced membrane potential oscillations and insulin secretion by murine β-cells," Pflugers Archiv-European Journal of Physiology, vol. 468, no. 4, pp. 573–591, 2016.
[12] M. Dufer, B. Gier, D. Wolpers, P. Krippeit-Drews, P. Ruth, and G. Drews, "Enhanced glucose tolerance by SK4 channel inhibition in pancreatic β-cells," Diabetes, vol. 58, no. 8, pp. 1835–1843, 2009.
[13] C. Simard, L. Salle, R. Rouet, and R. Guimard, ""Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle," British Journal of Pharmacology, vol. 165, no. 7, pp. 2354–2364, 2012.
[14] M. Anlauf, D. Wieben, A. Perren et al., "Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis," The American Journal of Surgical Pathology, vol. 29, no. 4, pp. 524–533, 2005.